GlassScriptPhysician profile
H Scott Tyson
NPI 1851386585
$3,333.84
in general payments reported to CMS, 2019-2025
25 companies · $486 in 2025
The $486 reported for 2025 was more than what 93% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $298 · 2020: $157 · 2021: $480 · 2022: $534 · 2023: $707 · 2024: $671 · 2025: $486.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,864.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,863.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $831.82 | 2021-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $444.00 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $263.34 | 2021-2025 | Qelbree, Qelbree |
| Neos Therapeutics, LP | $235.74 | 2019-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Merck Sharp & Dohme LLC | $187.42 | 2019-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Collegium Pharmaceutical, INC. | $178.53 | 2025 | Jornay Pm |
| Pfizer INC. | $163.59 | 2019-2023 | |
| Tris Pharma INC | $160.92 | 2022-2025 | Dyanavel Xr, Onyda Xr |
| Glaxosmithkline, LLC. | $145.77 | 2022-2025 | Bexsero, Penmenvy |
| Kaleo, INC. | $143.10 | 2019-2023 | Auvi-Q |
| Cranial Technologies, INC | $119.13 | 2021-2025 | Doc Band |
| Ironshore Pharmaceuticals INC. | $71.83 | 2020-2024 | |
| Organon LLC | $67.23 | 2023-2025 | Nexplanon |
| Vertical Pharmaceuticals, LLC | $51.95 | 2019-2025 | Relexxii |
| Seqirus USA INC | $47.55 | 2023-2024 | Flucelvax, Flucelvax Quadrivalent |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $39.86 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $39.71 | 2019-2021 | |
| Sanofi Pasteur INC. | $21.14 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $20.57 | 2023 | Flumist Quadrivalent |
| Verrica Pharmaceuticals INC. | $20.15 | 2024 | Ycanth |
| Alexion Pharmaceuticals, INC. | $18.42 | 2024 | Strensiq |
| Adlon Therapeutics L.P. | $17.71 | 2021 | |
| Phadia US INC. | $17.20 | 2022 | |
| Nestle Healthcare Nutrition INC. | $13.78 | 2023 | |
| Sanofi-Aventis U.S. LLC | $13.38 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw H Tyson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.